We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 36% below its sector, cheaper than its peers on earnings.
Kilitch Drugs (India) Limited, established in 1978 and based in Mumbai, operates a comprehensive pharmaceutical enterprise involved in the development and distribution of a wide array of medicinal and related products, both within India and for export. Their extensive portfolio includes a broad spectrum of parenteral and nasal formulations, addressing various therapeutic categories such as gastroenterology, anti-inflammatory conditions, epilepsy, malaria, and infections, among others. These are available in diverse formats like ampoules, vials, and dry powder injectables, and feature specialized offerings like iron supplements, metered nasal drops, and proprietary brands such as Klavmox and Onecef. The company also manufactures a variety of oral medications, including tablets, capsules, dry syrups, gripe water, and oral liquids and powders, targeting areas such as antibiotics, anti-diabetics, and cardiovascular health. Beyond traditional pharmaceuticals, Kilitch offers effervescent tablets and powders, exemplified by products like ROIPAR, DUREGRA, ROIVIT, and PH-7, as well as nutritional products such as CELTINE. Their innovative solutions include C-Seal, a topical skin adhesive designed for closing wounds without sutures. Furthermore, their product range extends to cosmetics and herbal remedies, encompassing various oils, lotions, liquids, creams, and pastes for skin, personal, and hair care, alongside herbal supplements for conditions like sore throat, prostate issues, diabetes, obesity, and libido enhancement.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save KILITCH.NS and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
